Clinical trial underway to assess effectiveness and safety of potential Long Covid treatment
“A clinical trial is underway to assess the effectiveness and safety of sipavibart, AstraZeneca's long-acting monoclonal antibody designed to provide protection against Covid-19, as a potential treatment for Long Covid, the Nova Southeastern University (NSU) and the Schmidt Initiative for Long Covid (SILC) announced today.”
A clinical trial is underway to assess the effectiveness and safety of sipavibart, AstraZeneca's long-acting monoclonal antibody designed to provide protection against Covid-19, as a potential treatment for Long Covid, the Nova Southeastern University (NSU) and the Schmidt Initiative for Long Covid (SILC) announced today.